Cabaletta Bio Inc
For the period ended Mar 31, 2024. Filed May 15, 2024.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2024 · Filed May 15, 2024
CABA$1.30+1.6%Stored close · as of Nov 6, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Balance Sheets
| March 31,2024 | December 31,2023 | |
|---|---|---|
| Assets · (unaudited) | ||
| Current assets: | ||
| Cash and cash equivalents | $175,293 | $193,238 |
| Short-term investments | 48,552 | 48,011 |
| Prepaid expenses and other current assets | 3,635 | 3,241 |
| Total current assets | 227,480 | 244,490 |
| Property and equipment, net | 2,918 | 2,541 |
| Operating lease right-of-use assets | 7,691 | 4,910 |
| Other assets | 2,368 | 1,709 |
| Total Assets | $240,457 | $253,650 |
| Liabilities and stockholders’ equity | ||
| Current liabilities: | ||
| Accounts payable | $5,843 | $4,547 |
| Accrued and other current liabilities | 4,725 | 7,887 |
| Operating lease liabilities, current portion | 7,404 | 3,560 |
| Total current liabilities | 17,972 | 15,994 |
| Operating lease liabilities, net of current portion | 765 | 1,458 |
| Total Liabilities | 18,737 | 17,452 |
| Commitments and contingencies (see Notes 5 and 6) | ||
| Stockholders’ equity: | ||
| Preferred stock, $0.00001 par value: 10,000,000 shares authorized as of March 31, 2024 and December 31, 2023; no shares issued or outstanding at March 31, 2024 and December 31, 2023 | — | — |
| Voting and non-voting common stock, $0.00001 par value: 150,000,000 (143,590,481 voting and 6,409,519 non-voting) shares authorized as of March 31, 2024 and December 31, 2023; 48,249,115 (46,804,820 voting and 1,444,295 non-voting) shares issued and outstanding as of March 31, 2024 and 47,823,232 (46,378,937) voting and 1,444,295 non-voting) shares issued and outstanding as of December 31, 2023 | — | — |
| Additional paid-in capital | 480,042 | 469,396 |
| Accumulated other comprehensive loss | (38) | 39 |
| Accumulated deficit | (258,284) | (233,237) |
| Total stockholders’ equity | 221,720 | 236,198 |
| Total liabilities and stockholders’ equity | $240,457 | $253,650 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.